SFM
HZNP

Sphera Funds Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Sphera Funds Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-18,100
Closed -$293K – 133
2016
Q4 		$293K Buy
+18,100
New +$328K 0.07% 97
2015
Q4 		– Sell
-3,500
Closed -$6.94M – 146
2015
Q3 		$6.94M Buy
+3,500
New +$111K 0.89% 25

Other funds holding HZNP

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Sphera Funds Management's HZNP Position: Q2 2017 in Review

Sphera Funds Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 480,000 shares — an estimated $7.09M sold.

Sphera Funds Management first reported a position in HZNP in Q3 2015 and held it in 5 quarters. The position peaked at $9.7M in Q3 2016. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

  • Sphera Funds Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • Sphera Funds Management sold 480,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $7.09M.
  • Sphera Funds Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 5 quarters.
  • Sphera Funds Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $9.7M in Q3 2016.
  • 190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on Sphera Funds Management's 13F filing for Q2 2017, filed 9 Aug 2017.